Search filters

Filters

Clear All

Phase

  • 2
  • 6
  • 1
  • 5
  • 7
  • 23
  • 10
  • 23

Found 23 Pancreatitis trials

A listing of Pancreatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Effect of GLP-1 Agonist Therapy on Insulin Secretion in Adults with Pancreatic Insufficient Cystic Fibrosis and Abnormal Glucose Tolerance: a randomized open-label cross-over trial

18 years - 50 years
All genders
Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced -cell mass contributes to the insulin secretory defects that characterizes cystic fibrosis-related diabetes (CFRD), other modifiable determinants appear operative in the emergence and progression of abnormal glucose tolerance towards diabetes. Identifying interventions …

A Study of the Safety and Efficacy of Pancreatic Endocrine Cell Clusters Implanted Into the Omentum of Type 1 Diabetes Patients With Severe Hypoglycemia (SUGR)

18 years - 65 years
All genders
Phase 1/2
Interventional
This study will evaluate the safety, efficacy and durability of SR-02 administered to the omentum of patients of Type 1 diabetes with severe recurrent hypoglycemia. The study will also help establish the optimal treatment dose. Although this study is open to patients with all HLA or blood types, immunosuppression to …
 Does Apolipoprotein A-V (APOA5) the genetic code of a protein, affect the levels of triglycerides (a type of fat) in the blood,

Does Apolipoprotein A-V (APOA5) the genetic code of a protein, affect the levels of triglycerides (a type of fat) in the blood,

18 years - 99 years
All genders
The purpose of this study is to determine how changes in the genetic code of a protein called Apolipoprotein A-V (APOA5) may affect the levels of triglycerides (a type of fat) in the blood, and the risk of heart disease and acute pancreatitis. People who have these changes, as well …

The Role of the Microbiome in Inter-Individual Variability in NSAID Disposition and Response

18 years - 99 years
All genders
Phase 1
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used in the treatment of pain and inflammation. Mounting evidence indicates that rectal administration of NSAIDs is also effective in preventing pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP) by an unknown mechanism. Alterations in the salivary and fecal microbiome have been observed in patients with …
 Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer

18 years - 99 years
All genders
Phase 1
Interventional
This research study consists of a safety run-in phase and a randomized phase 2 study which include subjects with previously-untreated, metastatic pancreatic adenocarcinoma. In the run-in safety study, the safety of adding two formulations (IV or Oral) of paricalcitol to a standard chemotherapy program of gemcitabine and nab-paclitaxel will be …
 REVOLUTION: Trial to Evaluate Immunotherapy Combinations with Chemotherapy for the Treatment of Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma

REVOLUTION: Trial to Evaluate Immunotherapy Combinations with Chemotherapy for the Treatment of Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma

18 years - 99 years
All genders
Phase 1
This is a phase 1 study that enrolls subjects with metastatic pancreatic adenocarcinoma. The purpose of this study is to learn about the safety and efficacy of a combination of 4 study drugs: ipilimumab (ipi), nab-paclitaxel (nP), gemcitabine (gem), and hydroxychloroquine (HCQ). This is an open-label, non-randomized, exploratory platform trial …
 The Cancer of the Pancreas Screening-5

The Cancer of the Pancreas Screening-5

1 years - 99 years
All genders
The specific Aims of CAPS5 will be: Aim #1: To evaluate pancreatic fluid mutations and circulating pancreatic epithelial cells as accurate markers of neoplasia by comparing their prevalence in cases with sporadic pancreatic neoplasia to healthy and disease controls. Aim #2: To compare the prevalence of pancreatic fluid mutations and …

UPCC 10219: Phase II Study Of Stromal Changes Detected By DCE- and DW-MRI In Response To PEGPH20 Combined With Chemotherapy In Subjects With Locally-Advanced Pancreatic Cancer

All genders
Phase 2
The research study is being conducted to determine the effects of PEGPH20 plus chemotherapy treatment on the MRI characteristics of pancreatic cancer tumors. Subjects will receive Gemcitabine, Abraxane, and PEGPH20.
 APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1  BRCA2 or PALB2 Mutation

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1 BRCA2 or PALB2 Mutation

18 years - 99 years
All genders
The purpose of this study is to compare the usual treatment alone to using one year of olaparib. We will enroll subject who have been diagnosed with pancreatic cancer and have undergone surgery to remove the cancer. Only patients who are found to have a BRCA1, BRCA2 or PALB2 mutation …

A Study to Evaluate the Efficacy and Safety of Belzutifan Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)

12 years - 99 years
All genders
Phase 2
Interventional
This is a study to evaluate the efficacy and safety of Belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (pNET). The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST …
11 - 20 of 23